€102.50
0.00% day before yesterday
Frankfurt, Aug 08, 02:47 pm CET
ISIN
NL0012044747
Symbol
RDC
Index

Redcare Pharmacy Target price 2025 - Analyst rating & recommendation

Redcare Pharmacy Classifications & Recommendation:

Buy
75%
Hold
13%
Sell
13%

Redcare Pharmacy Price Target

Target Price €173.40
Price €102.50
Potential
Number of Estimates 13
13 Analysts have issued a price target Redcare Pharmacy 2026 . The average Redcare Pharmacy target price is €173.40. This is higher than the current stock price. The highest price target is
€224.70 119.22%
register free of charge
, the lowest is .
A rating was issued by 16 analysts: 12 Analysts recommend Redcare Pharmacy to buy, 2 to hold and 2 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Redcare Pharmacy stock has an average upside potential 2026 of . Most analysts recommend the Redcare Pharmacy stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Billion € 2.37 3.02
31.79% 27.31%
EBITDA Margin 1.26% 2.16%
54.51% 71.94%
Net Margin -1.92% -0.73%
186.50% 61.93%

12 Analysts have issued a sales forecast Redcare Pharmacy 2025 . The average Redcare Pharmacy sales estimate is

€3.0b
Unlock
. This is
12.77% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
€3.2b 19.09%
Unlock
, the lowest is
€2.9b 8.14%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 €2.4b 31.79%
2025
€3.0b 27.31%
Unlock
2026
€3.6b 20.11%
Unlock
2027
€4.3b 18.70%
Unlock
2028
€4.9b 13.01%
Unlock
2029
€5.6b 14.15%
Unlock
2030
€5.9b 6.34%
Unlock
2031
€6.4b 7.95%
Unlock
2032
€6.7b 5.54%
Unlock

14 Analysts have issued an Redcare Pharmacy EBITDA forecast 2025. The average Redcare Pharmacy EBITDA estimate is

€65.2m
Unlock
. This is
111.83% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
€85.1m 176.41%
Unlock
, the lowest is
€52.4m 70.17%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 €29.8m 40.04%
2025
€65.2m 118.88%
Unlock
2026
€128m 96.96%
Unlock
2027
€189m 47.07%
Unlock
2028
€275m 45.85%
Unlock
2029
€358m 30.00%
Unlock

EBITDA Margin

2024 1.26% 54.51%
2025
2.16% 71.94%
Unlock
2026
3.54% 63.89%
Unlock
2027
4.39% 24.01%
Unlock
2028
5.66% 28.93%
Unlock
2029
6.45% 13.96%
Unlock

14 Redcare Pharmacy Analysts have issued a net profit forecast 2025. The average Redcare Pharmacy net profit estimate is

€-22.1m
Unlock
. This is
36.52% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
€-1.1m 96.96%
Unlock
, the lowest is
€-33.9m 2.75%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 €-45.5m 277.57%
2025
€-22.1m 51.32%
Unlock
2026
€28.4m 228.20%
Unlock
2027
€71.2m 151.11%
Unlock
2028
€155m 118.12%
Unlock
2029
€249m 60.33%
Unlock

Net Margin

2024 -1.92% 186.50%
2025
-0.73% 61.93%
Unlock
2026
0.78% 206.85%
Unlock
2027
1.66% 112.82%
Unlock
2028
3.20% 92.77%
Unlock
2029
4.49% 40.31%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share -2.27 -1.10
260.32% 51.54%
P/E negative
EV/Sales 0.72

14 Analysts have issued a Redcare Pharmacy forecast for earnings per share. The average Redcare Pharmacy EPS is

€-1.10
Unlock
. This is
36.42% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
€-0.05 97.11%
Unlock
, the lowest is
€-1.69 2.31%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 €-2.27 260.32%
2025
€-1.10 51.54%
Unlock
2026
€1.41 228.18%
Unlock
2027
€3.54 151.06%
Unlock
2028
€7.73 118.36%
Unlock
2029
€12.39 60.28%
Unlock

P/E ratio

Current -59.25 80.44%
2025
-93.14 57.20%
Unlock
2026
72.65 178.00%
Unlock
2027
28.93 60.18%
Unlock
2028
13.27 54.13%
Unlock
2029
8.27 37.68%
Unlock

Based on analysts' sales estimates for 2025, the Redcare Pharmacy stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 0.81 36.22%
2025
0.72 10.98%
Unlock
2026
0.60 16.74%
Unlock
2027
0.51 15.76%
Unlock
2028
0.45 11.53%
Unlock
2029
0.39 12.38%
Unlock
2030
0.37 5.97%
Unlock
2031
0.34 7.35%
Unlock
2032
0.32 5.27%
Unlock

P/S ratio

Current 0.79 37.75%
2025
0.70 11.33%
Unlock
2026
0.58 16.74%
Unlock
2027
0.49 15.76%
Unlock
2028
0.43 11.52%
Unlock
2029
0.38 12.39%
Unlock
2030
0.36 5.95%
Unlock
2031
0.33 7.37%
Unlock
2032
0.31 5.26%
Unlock

Current Redcare Pharmacy Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
METZLER EQUITIES
Locked
Locked
Locked Jul 17 2025
JEFFERIES
Locked
Locked
Locked Jul 16 2025
BAADER HELVEA EQUITY RESEARCH
Locked
Locked
Locked Jul 02 2025
BERENBERG
Locked
Locked
Locked Jun 30 2025
HSBC
Locked
Locked
Locked May 25 2025
HAUCK AUFHAEUSER INVESTMENT BANKING
Locked
Locked
Locked May 06 2025
MWB RESEARCH AG
Locked
Locked
Locked May 06 2025
Analyst Rating Date
Locked
METZLER EQUITIES:
Locked
Locked
Jul 17 2025
Locked
JEFFERIES:
Locked
Locked
Jul 16 2025
Locked
BAADER HELVEA EQUITY RESEARCH:
Locked
Locked
Jul 02 2025
Locked
BERENBERG:
Locked
Locked
Jun 30 2025
Locked
HSBC:
Locked
Locked
May 25 2025
Locked
HAUCK AUFHAEUSER INVESTMENT BANKING:
Locked
Locked
May 06 2025
Locked
MWB RESEARCH AG:
Locked
Locked
May 06 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today